S&P 500   4,088.85
DOW   32,654.59
QQQ   306.17
S&P 500   4,088.85
DOW   32,654.59
QQQ   306.17
S&P 500   4,088.85
DOW   32,654.59
QQQ   306.17
S&P 500   4,088.85
DOW   32,654.59
QQQ   306.17

ImmunoPrecise Antibodies News Headlines

$4.89
+0.06 (+1.24%)
(As of 05/17/2022 12:00 AM ET)
Add
Compare
Today's Range
$4.76
$5.23
50-Day Range
$3.64
$6.08
52-Week Range
$3.51
$16.47
Volume
13,215 shs
Average Volume
33,796 shs
Market Capitalization
$99.75 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
-0.5
Get ImmunoPrecise Antibodies News Delivered to You Automatically

Sign up to receive the latest news and ratings for IPA and its competitors with MarketBeat's FREE daily newsletter.

Media Mentions By Week

ImmunoPrecise Antibodies Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

IPA
News Sentiment

1.87

0.46

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

IPA Articles
This Week

0

0

IPA Articles
Average Week



ImmunoPrecise Antibodies (NASDAQ:IPA) News Headlines Today

SourceHeadline
benzinga.com logoIPA's Subsidiary BioStrand Secures Second...
benzinga.com - May 9 at 10:35 AM
MarketBeat logoImmunoPrecise Antibodies (NASDAQ:IPA) Trading Down 0.5%
americanbankingnews.com - May 3 at 1:36 AM
finance.yahoo.com logoIPA’s Advanced PolyTope® TATX-03, a Multi-Antibody Cocktail, Potently Prevents In Vitro Infection of Cells by the Currently Dominant Omicron Sublineage BA.2, in Addition to all Other Variants of Concern
finance.yahoo.com - April 20 at 12:57 PM
finance.yahoo.com logoIPA Completes Acquisition of Belgian Technology Companies BioStrand, BioKey, and BioClue – Adding Artificial Intelligence-Driven Analytics to its Antibody Discovery Capabilities and Offerings
finance.yahoo.com - April 14 at 12:05 PM
finance.yahoo.com logoIPA Announces Agreement to Acquire BioStrand BV – Revolutionizing Biotherapeutics with Methodology to Encode Omics and Power Drug Development with Advanced Artificial Intelligence
finance.yahoo.com - March 29 at 11:32 AM
finance.yahoo.com logoImmunoPrecise Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2022
finance.yahoo.com - March 16 at 8:25 AM
finance.yahoo.com logoIPA Selected to Work with Elektrofi on COVID-19 Therapeutic Delivery and Future Pandemic Preparation under SBIR Contract from Defense Health Agency within US Department of Defense
finance.yahoo.com - March 14 at 10:50 AM
finance.yahoo.com logoIPA Updates on Investigational New Drug (IND) Enabling Program for PolyTope® TATX-03
finance.yahoo.com - March 9 at 10:10 AM
finance.yahoo.com logoImmunoPrecise Sets Third Quarter Fiscal 2022 Financial Results and Recent Business Highlights Conference Call for Wednesday, March 16th at 10:30 a.m. ET
finance.yahoo.com - March 8 at 9:52 AM
seekingalpha.com logoImmunoPrecise rises 11% as PolyTope shows neutralizing potency against Omicron
seekingalpha.com - January 31 at 10:19 AM
finance.yahoo.com logoImmunoPrecise Relocates European Subsidiary to LEED Certified Campus to Continue to Advance its Antibody Research Operations and Environmental Sustainability
finance.yahoo.com - January 18 at 12:59 PM
finance.yahoo.com logoInvestors in ImmunoPrecise Antibodies (CVE:IPA) have made a impressive return of 113% over the past three years
finance.yahoo.com - January 16 at 12:51 PM
finance.yahoo.com logoImmunoPrecise Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2022
finance.yahoo.com - December 7 at 10:57 AM
benzinga.com logoImmunoPrecise Antibodies Says Polytope Reaches Multiple Milestones; Co Says Has Commenced Omicron Variant Analysis
benzinga.com - November 30 at 12:57 PM
finance.yahoo.com logoImmunoPrecise to Present at the Benchmark Company’s Discovery One-on-One Virtual Video Investor Conference on Thursday December 2, 2021
finance.yahoo.com - November 24 at 12:30 PM
finance.yahoo.com logoImmunoPrecise Announces At-The-Market Facility of up to US$50 Million
finance.yahoo.com - October 13 at 8:25 PM
finance.yahoo.com logoImmunoPrecise’s Dutch Subsidiary Receives French Research Tax Credit (CIR) Accreditation
finance.yahoo.com - September 8 at 12:15 PM
finance.yahoo.com logoImmunoPrecise Announces Participation at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13-15, 2021 (Virtual Conference)
finance.yahoo.com - September 7 at 10:24 AM
finance.yahoo.com logoImmunoPrecise Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2022
finance.yahoo.com - September 3 at 10:39 AM
finance.yahoo.com logoImmunoPrecise Welcomes Vice President of Client Relations and Vice President of Marketing to its Leadership Team, Accelerating Its Growth and Expansion Plans
finance.yahoo.com - August 4 at 9:59 AM
finance.yahoo.com logoShould ImmunoPrecise Antibodies (CVE:IPA) Be Disappointed With Their 23% Profit?
finance.yahoo.com - July 20 at 9:58 AM
nasdaq.com logoImmunoPrecise Antibodies Ltd. Common Stock (IPA)
nasdaq.com - July 13 at 12:50 AM
finance.yahoo.com logoHistopathology Preclinical Data from ImmunoPrecise’s Polytope™ Program Confirms Lung Inflammation Reduction
finance.yahoo.com - June 17 at 1:20 PM
finance.yahoo.com logoPreclinical Data from ImmunoPrecise’s Drug Pipeline to be Presented During the BIO International Partnering Event
finance.yahoo.com - June 15 at 11:30 AM
finance.yahoo.com logoImmunoPrecise Moves SARS-CoV-2 PolyTope™ Cocktail Program’s Path Toward IND Filing
finance.yahoo.com - May 20 at 8:28 AM
finance.yahoo.com logoImmunoPrecise Launches TATX-112 Candidate Antibody Program, for the Treatment of Cancer and Alzheimer’s Disease
finance.yahoo.com - April 8 at 8:15 AM
finance.yahoo.com logoImmunoPrecise Identifies a Unique Antibody, 23-H7, That Demonstrates In Vivo Efficacy, an Alternative Mechanism of Action and Binds all Tested SARS-CoV-2 Variants of Concern
finance.yahoo.com - March 25 at 11:52 AM
finance.yahoo.com logoImmunoPrecise Reports Financial Results and Recent Business Highlights for Third Quarter of 2021 Fiscal Year
finance.yahoo.com - March 17 at 11:10 PM
finance.yahoo.com logoImmunoPrecise Announces Participation at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021 (Virtual Conference)
finance.yahoo.com - March 4 at 10:17 AM
marketwatch.com logoIPAAnnounces Closing of Over-Allotment Option Associated with the Recently CompletedBought Deal Offering of Common Shares
marketwatch.com - February 12 at 3:03 AM
marketwatch.com logoIPAAnnounces Closing of $21.7 MillionBought Deal Offering of Common Shares
marketwatch.com - February 9 at 6:41 AM
finance.yahoo.com logoIPA Announces Closing of $21.7 Million Bought Deal Offering of Common Shares
finance.yahoo.com - February 8 at 5:45 PM
finance.yahoo.com logoIPA Announces $10.0 Million Bought Deal Offering of Common Shares
finance.yahoo.com - February 3 at 7:19 PM
finance.yahoo.com logoIf You Had Bought ImmunoPrecise Antibodies (CVE:IPA) Shares Three Years Ago You'd Have Earned 555% Returns
finance.yahoo.com - January 26 at 8:26 AM
Get ImmunoPrecise Antibodies News Delivered to You Automatically

Sign up to receive the latest news and ratings for IPA and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 5/18/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.